In the case of targeting CD19 in acute lymphoblastic leukaemia, 30–70 percent of patients showed downregulation or loss of target CD19 expression after treatment (Liu et al., 2021; Maude et al., 2015). Here, CD19 is linked to acute lymphoblastic leukemia.